Utility of $^{99m}$TcO$_4^-$ static imaging for detecting metastatic lesions in differentiated thyroid cancer.

Hongbo Gao1#, Wei Song1#, Yuqing Di1, Haichun Liu1, Yujun Shao1, Linlin Ma1, Zheng Li1, Congjun Jin1, Huiliang Xie1, Chunyuan Zhao1, Lijun Yang1, Xiaoyong Zhang1*, Yonghui Chen2*

1Department of Radionuclide Treatment Center, Beijing 401 Hospital of Chinese Nuclear Industry, Beijing, PR China
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

#These authors contributed equally to this work

Abstract

The aim of this study was to evaluate the utility of thyroid static imaging with $^{99m}$TcO$_4^-$ for detecting metastatic lesions following surgery in patients with Differentiated Thyroid Cancer (DTC). A total of 420 consecutive post-total thyroidectomy patients with pathologically diagnosed differentiated thyroid cancer underwent thyroid static imaging with $^{99m}$TcO$_4^-$ before $^{131}$I treatment to evaluate the size, location, and function of the residual thyroid. They also underwent $^{131}$I whole-body scanning ($^{131}$I-WBS), as well as single-photon emission computed tomography/computed tomography fusion imaging (when necessary), for evaluation of the lesions. The detection rates of thyroid static imaging with $^{99m}$TcO$_4^-$ and $^{131}$I-WBS (therapeutic dose) were 83.81% and 98.33%, respectively. The sensitivity of $^{99m}$TcO$_4^-$ thyroid static imaging was 85.2%, and the rate of detection with both $^{99m}$TcO$_4^-$ static imaging and $^{131}$I-WBS was 85.48%. The use of $^{99m}$TcO$_4^-$ thyroid static imaging identified metastatic lesions in 10 patients; thus, the original planned treatment dose and protocol were adjusted in these patients. Based on our findings, we conclude that thyroid static imaging with $^{99m}$TcO$_4^-$ can be used to evaluate the residual thyroid tissue after thyroid carcinoma resection and can identify metastatic lesions, thereby helping to guide the selection of the $^{131}$I treatment dose.

Keywords: Differentiated thyroid carcinoma, $^{99m}$TcO$_4^-$-thyroid static imaging, $^{131}$I whole body scanning.

Introduction

Thyroid carcinoma is the most common malignant tumor of the endocrine system, out of which more than 90% are cases of Differentiated Thyroid Carcinomas (DTCs). Total thyroidectomy or near total thyroidectomy combined with $^{131}$I thyroid remnant ablation, as well as thyroid hormone suppressive therapy, is the main approach recommended by the current treatment guidelines for DTC [1]. To understand the patients’ surgical conditions and to determine the optimal $^{131}$I dose before treatment, it is often necessary to evaluate the size, location, and function of the residual thyroid tissue.

Although $^{131}$I imaging is commonly used to evaluate the residual thyroid tissue worldwide, it is both expensive and difficult to access in China [2-4]; therefore, $^{131}$I imaging is used as an alternative. However, some researchers consider that small doses of $^{131}$I can cause the so-called “stunning” phenomenon observed in diagnostic imaging [3,5] and that this phenomenon alters the ultimate therapeutic effect. In contrast, other researchers have reported that thyroid stunning has no effect on the therapeutic outcome [6,7]. Therefore, it is necessary to identify the most suitable imaging agent to assess the residual thyroid tissue.

Because $^{99m}$TcO$_4^-$ can appropriately reflect the sodium iodide symporter (NIS) expression [8,9], thyroid static imaging with $^{99m}$TcO$_4^-$ is often used clinically to assess the size, location, and function of the residual thyroid tissue. Although several studies have reported that $^{99m}$TcO$_4^-$ thyroid static imaging can occasionally detect metastatic thyroid cancer, owing to its limited sensitivity as well as the fact that its diagnostic capacity may depend on high levels of Thyroid-Stimulating Hormone (TSH) in stimulated states, this approach is not widely used [10-12].

Moreover, some studies have shown that $^{99m}$TcO$_4^-$ systemic scanning can reveal metastatic DTC lesions in the neck and chest [13], while other studies have revealed that $^{99m}$TcO$_4^-$ thyroid static imaging cannot only accurately assess the size, location, and function of residual thyroid tissue but that, in some cases of DTC, it can also reveal metastatic lesions, such as lymph node, lung, or bone metastases, thereby helping

Accepted on September 11, 2017
physicians to promptly adjust the patients’ clinical stages and modify their treatment plans.

The presence of NIS protein is the underlying mechanism for the uptake of $^{131}$I and $^{99m}$TcO$_4^-$ by cancer tissues. However, it is unclear why $^{99m}$TcO$_4^-$ thyroid static imaging can only reveal metastatic lesions in certain types of DTC, instead of in all types. This may be the result of high NIS expression in the detected metastatic lesions. Lesions with high expression of NIS are also likely to have high $^{131}$I uptake ability, implying a good therapeutic effect with $^{131}$I and consequently a better prognosis.

In the present study, we aimed to investigate whether metastatic lesions of DTC detected via $^{99m}$TcO$_4^-$ thyroid static imaging respond well to $^{131}$I therapy, and whether patients with these lesions have a better prognosis. The main objective of the study was to determine whether $^{99m}$TcO$_4^-$ thyroid static imaging can be used as an alternative to $^{131}$I imaging for the evaluation of $^{131}$I treatment. The traditional approach is to use small doses of $^{131}$I diagnostic imaging for preoperative evaluations; however, as mentioned above, the use of this method is limited due to controversy regarding thyroid stunning. On the other hand, the use of $^{99m}$TcO$_4^-$ imaging will not result in stunning, with the advantages of high sensitivity and specificity and low radiation dosage. Thus, we moreover aimed to determine the clinical value of $^{99m}$TcO$_4^-$ thyroid static imaging, and whether it has unique advantages over other imaging methods.

**Materials and Methods**

**Subjects**

A total of 420 consecutive post-total-thyroidectomy patients with pathologically diagnosed DTC who underwent $^{131}$I therapy from March 2014 to September 2015 in the Beijing 401 Hospital of the Chinese Nuclear Industry were selected and retrospectively analysed. Prior to treatment with $^{131}$I, $^{99m}$TcO$_4^-$ thyroid static imaging was performed to evaluate the size, location, and function of the residual thyroid tissue, and if any abnormal findings were observed, Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) fusion imaging was also performed. After $^{131}$I treatment, $^{131}$I Whole-Body Scanning ($^{131}$I-WBS) and SPECT/CT fusion imaging were performed for comparison.

The data of the 420 patients showed that $^{99m}$TcO$_4^-$ thyroid static imaging demonstrated areas of abnormal $^{99m}$TcO$_4^-$ concentration in 10 patients before $^{131}$I treatment (3 men and 7 women, age range 19-59 y). There were 8 cases of papillary thyroid carcinoma (including 3 cases of the follicular variant of papillary thyroid carcinoma and 2 cases of thyroid follicular carcinoma). Among these, $^{131}$I-WBS, SPECT/CT fusion imaging, and sonography confirmed lymph node metastases in 7, lung metastases in 4, and bone metastasis in 1, with simultaneous lymph node and lung metastases present in 2 patients.

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Beijing 401 Hospital. Written informed consent was obtained from all participants.

**$^{99m}$TcO$_4^-$ thyroid static imaging**

A total of 185 MBq (5 mCi) of $^{99m}$TcO$_4^-$ (Atom Hitech Co., Ltd., Beijing, China) was intravenously injected, followed by thyroid static imaging 20 min later. Each patient was placed in the supine position with normal head position and the neck raised to fully expose the thyroid. Normal anteposition images were collected using a SIEMENS e.cam SPECT instrument (Siemens Medical Solutions USA, Inc., Malvern, PA, USA) and a Philips BrightView XCT (Philips Medical Systems, Cleveland, OH, USA) SPECT/CT instrument (equipped with low-energy high-resolution collimators). The matrix was $256 \times 256$ and the acquisition count was 150 k. Any foci outside the thyroid that showed obvious $^{131}$I uptake, as well as lesions with evaluation and quantification difficulties, were further evaluated with SPECT/CT fusion imaging.

**$^{131}$I-WBS**

Each patient was orally administered 3.7-7.4 GBq (100-200 mCi) of $^{131}$I (Atom-Hitech Co., Ltd.) after fasting and underwent $^{131}$I-WBS 3 d later. During the procedure, each patient was placed in the supine position with a normal head position and the neck raised, with the hands placed on along the side of the body. SPECT and SPECT/CT (bed-moving speed 12 cm/min, equipped with high-energy universal collimators) were used for acquisition. The matrix was $256 \times 1024$. Any obvious foci outside the thyroid showed obvious $^{131}$I uptake, as well as lesions with qualification and quantification difficulties, were subjected to further $^{131}$I SPECT/CT fusion imaging.

**Image analysis**

Two nuclear medicine physicians interpreted the films using the double-blind method; when the conclusions were not consistent, they re-read the films together and arrived at a consensus through discussion. The following image diagnostic criteria were applied: (1) to determine whether the results of the two imaging methods were consistent, the existence of a radiation uptake focus in the cervical thyroid area was diagnosed as positive; (2) to determine films with abnormalities, the residual thyroid and physiological uptake were diagnosed as negative, while abnormal uptake in the lymph nodes, lungs, bones, and other parts was diagnosed as positive.

**Results**

**Imaging results**

The results of the two imaging methods are shown in Table 1. The detection rates of $^{99m}$TcO$_4^-$ thyroid static imaging and $^{131}$I-WBS (therapeutic dose) were 83.81% (352/420) and 98.33%.
Utility of $^{99m}$TcO$_4^-$ static imaging for detecting metastatic lesions in differentiated thyroid cancer

(413/420), respectively. The sensitivity of $^{99m}$TcO$_4^-$ thyroid static imaging was 85.2% (352/413), and the rate of detection via both $^{99m}$TcO$_4^-$ thyroid static imaging and $^{131}$I-WBS was 85.48% (359/420).

Table 1. Results of DTC by two imaging methods (n).

<table>
<thead>
<tr>
<th>$^{99m}$TcO$_4^-$</th>
<th>$^{131}$I-WBS</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Static imaging</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Positive</td>
<td>352</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>61</td>
<td>7</td>
</tr>
<tr>
<td>Sum</td>
<td>413</td>
<td>7</td>
</tr>
</tbody>
</table>

Analysis of $^{99m}$TcO$_4^-$ static imaging

Among the 420 patients, 10 patients were found to have lesions with abnormal uptake by $^{99m}$TcO$_4^-$ static imaging. These were confirmed as metastases by $^{131}$I-WBS, SPECT/CT fusion imaging, and ultrasound after treatment; the incidence was 2.38% (10/420), and the cancer types specifically involved were papillary thyroid cancer in 8 cases, the follicular variant of papillary thyroid carcinoma in 3 cases, and thyroid follicular carcinoma in 2 cases. Lymph node, lung, and bone metastases were present in 7, 4, and 1 case, respectively; among these, lymph node and lung metastases occurred simultaneously in 2 cases.

The original planned therapeutic dose was modified in these 10 patients according to the $^{99m}$TcO$_4^-$ static imaging results. The originally planned $^{131}$I treatment dose was 100 mCi; patients 1-9 and 10 instead received 150 and 200 mCi of $^{131}$I for thyroid remnant or lesion ablation, respectively. Surgical management of the lymph nodes was recommended for patients 1-5 after $^{131}$I treatment, with a potential requirement for secondary surgery in some patients, while multiple $^{131}$I lesion scavenging was recommended for patients 6-10 (Table 2).

Table 2. Clinical data of the 10 DTC patients with metastatic lesions revealed by $^{99m}$TcO$_4^-$ static imaging.

<table>
<thead>
<tr>
<th>No</th>
<th>Gender</th>
<th>Age (y)</th>
<th>Pathological type</th>
<th>Abnormalities in $^{99m}$TcO$_4^-$ imaging</th>
<th>Abnormalities in $^{131}$I-WBS</th>
<th>$^{131}$I SPECT/CT fusion imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>30</td>
<td>Thyroid carcinoma</td>
<td>Punctiform radioactive concentration area on the right clavicle</td>
<td>Equivalent to one punctiform abnormal intake focus on the right clavicle</td>
<td>Abnormal intake focus on the right clavicle, considered to be lymph node metastasis</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>35</td>
<td>Thyroid carcinoma (follicular variant)</td>
<td>Punctiform radioactive concentration area on the sternal plane</td>
<td>Equivalent to one punctiform abnormal intake focus on the superior sternal fossa</td>
<td>Abnormal intake focus on the superior sternal fossa, considered to be lymph node metastasis</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>44</td>
<td>Thyroid carcinoma</td>
<td>Punctiform radioactive concentration area on the superior sternal fossa</td>
<td>Equivalent to one punctiform abnormal intake focus on the superior sternal fossa</td>
<td>Abnormal intake focus on the superior sternal fossa, considered to be lymph node metastasis</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>49</td>
<td>Thyroid carcinoma</td>
<td>Multiple punctiform radioactive concentration areas on the upper mediastinal area</td>
<td>Multiple punctiform and lumpy abnormal intake foci on the upper mediastinal area</td>
<td>Abnormal intake foci on the upper mediastinal area, considered to be lymph node metastasis</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>26</td>
<td>Thyroid carcinoma</td>
<td>Multiple punctiform radioactive concentration areas on the left lateral neck</td>
<td>Multiple punctiform abnormal intake foci on the left lateral neck</td>
<td>Abnormal intake foci on the left lateral neck, considered to be lymph node metastasis</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>32</td>
<td>Thyroid carcinoma (follicular variant)</td>
<td>Multiple punctiform radioactive concentration areas on the mediastinum and bilateral chest</td>
<td>Multiple punctiform abnormal intake foci on the mediastinum and bilateral chest</td>
<td>Abnormal intake foci on the mediastinum and lungs, considered to be lymph node metastasis and lung metastasis</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>19</td>
<td>Thyroid carcinoma</td>
<td>Multiple punctiform radioactive concentration areas on the bilateral chest</td>
<td>Multiple punctiform abnormal intake foci on the bilateral chest</td>
<td>Abnormal intake foci in the bilateral chest, considered to be multiple lung metastases</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>53</td>
<td>Thyroid carcinoma</td>
<td>Multiple punctiform radioactive concentration areas on the bilateral chest</td>
<td>Multiple punctiform abnormal intake foci on the bilateral chest</td>
<td>Abnormal intake foci on the bilateral chest, considered to be multiple lung metastases</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>56</td>
<td>Thyroid carcinoma</td>
<td>Multiple punctiform radioactive concentration areas on the neck, upper mediastinum, and bilateral chest</td>
<td>Multiple punctiform abnormal intake foci on the neck, mediastinum, and bilateral chest</td>
<td>Abnormal intake foci on the neck, mediastinum, and lungs, considered to be neck node metastasis and multiple lung metastases</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>59</td>
<td>Thyroid carcinoma (follicular variant)</td>
<td>Multiple punctiform and irregular radioactive concentration areas on the anterior cervical area</td>
<td>One lumpy abnormal intake focus on the anterior cervical area</td>
<td>Abnormal intake foci on the C7 vertebra, considered to be bone metastasis</td>
</tr>
</tbody>
</table>
**Representative typical images**

The typical image criteria were defined as clear functional imaging and clear positioning of the fault image, with representative lymph node, bone, or lung metastasis. The image selection only considers factors related to image quality, and not variables related to clinical staging, pathology, age, sex, and other factors.

Typical case 1 was a 56 y old woman diagnosed with thyroid follicular cancer. Thyroid static imaging before the 131I treatment revealed multiple nodular areas of radioactive concentration in the neck, upper mediastinum, and bilateral thorax, resulting in a diagnosis of cervical and mediastinum lymph node metastases, along with bilateral lung metastases (Figure 1A). The patient was confirmed to have lymph node and lung metastases of thyroid follicular carcinoma by 99mTcO4- cervical SPECT/CT fusion imaging, 131I-WBS, and 131I cervical/thoracic SPECT/CT fusion imaging (Figure 1D).

**Figure 1.** Typical case 1, female, 56 y old, diagnosed as thyroid follicular cancer, cervical and mediastinum lymph nodule metastasis, bilateral lung metastasis. A: 99mTcO4- cervical SPECT/CT fusion imaging: multiple nodular radioactive concentration areas in the neck, upper mediastinum, and bilateral thoraces; B: 131I cervical/thoracic SPECT/CT fusion imaging: multiple nodular radioactive concentration areas in the neck, upper mediastinum, and bilateral lungs; C: 131I whole body imaging: multiple nodular abnormal I intake foci in the neck, upper mediastinum, and bilateral thoraces; D: 131I cervical/thoracic SPECT/CT fusion imaging: multiple abnormal I intake foci in the neck, upper mediastinum, and bilateral lungs, so the patient was diagnosed as cervical lymph node metastasis, upper mediastinmal lymph node metastasis, and multiple metastases in the bilateral lungs.

Typical case 2 was a 59 y old woman diagnosed with the follicular variant of papillary thyroid carcinoma. Thyroid static imaging before the 131I treatment revealed punctate and irregular areas of radioactive concentration; these areas represented the residual thyroid tissue, as well as possible bone metastases (Figure 2A). The punctate areas of radioactive concentration were confirmed as residual thyroid tissue and the irregular areas of radioactive concentration were confirmed as cervical metastasis of the follicular variant of papillary thyroid carcinoma by 99mTcO4- cervical SPECT/CT fusion imaging, 131I-WBS, and 131I cervical/thoracic SPECT/CT fusion imaging (Figures 2B-2D).

**Figure 2.** Typical case 2, female, 59 y old, diagnosed as follicular variant of papillary thyroid carcinoma: C7 vertebral bone metastasis. A: 99mTcO4- thyroid static imaging: punctate and irregular radioactive concentration areas anterior to the neck; B: 99mTcO4- cervical/thoracic SPECT/CT fusion imaging: punctate radioactive concentration areas in the thyroid gland anterior to the neck; C: 131I whole body imaging: one clump abnormal I intake focus; D: 131I SPECT/CT fusion imaging: the abnormal I intake focus before the neck is the residual thyroid tissue; the abnormal I intake at C7 vertebral body is considered as bone metastasis.

**Discussion**

Normal thyroid tissue has the NIS-mediated ability to perform selective uptake and accumulation of iodine. The elements Tc and iodine belong to the same family, and 99mTcO4- is very similar to the inorganic iodine ion; thus, thyroid tissue can also take up and concentrate Tc. However, 99mTcO4- cannot undergo further metabolism after it enters the thyroid cells, nor can it participate in the synthesis of thyroid hormones; hence, it can only reflect the uptake function of thyroid cells and not the metabolic function of iodine. The use of 99mTcO4- has a long history in the diagnosis of thyroid disease due to its valuable imaging features. Currently, 99mTcO4- is clinically used for thyroid static imaging to visualize the location, shape, size, and functional status of the thyroid.

Thyroid cancer is the most common endocrine system malignancy, accounting for 1.1% of systemic malignancies [14]. In recent years, a continued increase in the incidence of thyroid cancer has been observed, among which more than 90% of cases are DTC [15]. Cervical lymph node metastasis of DTC is common, and the most common locations of distant metastasis are the lungs and bone. Membrane expression of NIS is decreased in thyroid cancer cells. Therefore, in most preoperative routine thyroid static imaging studies, the cancer tissue shows a "cooled node" or "cold node," indicating reduced 99mTcO4- uptake. When the normal thyroid tissue has
not been completely removed, metastatic lesions that concentrate $99mTcO_4^-$ are rare. Only a small number of cervical lymph node metastases with $99mTcO_4^-$ concentration have been reported in China, and no case of DTC with multiple metastatic lesions revealed by $99mTcO_4^-$ thyroid static imaging has been reported. Further, only a few cases describing the uptake of Tc by thyroid cancer tissue have been reported in other countries [16-18]. Highly-differentiated DTC has a function similar to that of normal thyroid tissue. Therefore, $99mTcO_4^-$ may also be taken up by highly-differentiated thyroid cancer and its metastatic lesions.

The results of this study showed that the sensitivity of $99mTcO_4^-$ thyroid static imaging was 85.2%, exhibiting good consistency with postoperative $131I$-WBS (with a coincidence rate of 85.48%), similar to the findings of a prospective study by Khammash et al. that examined 66 patients with residual thyroid tissue after thyroid cancer resection [19]. The study of Ozdemir et al. [20] further showed that, compared with the standard of $131I$-WBS after treatment, the sensitivity, specificity, and positive predictive value of $99mTcO_4^-$ thyroid static imaging were 72.2%, 70.5%, and 97.4%, respectively, and the authors thus concluded that $99mTcO_4^-$ static thyroid imaging was very effective in assessing residual thyroid tissue and that it was helpful to determine the proper dose of $131I$ treatment, which was consistent with the results of the present study. The benefits of $99mTcO_4^-$ thyroid static imaging include that it can accurately assess the status of the residual thyroid tissue, that it can be used to determine therapeutic doses to avoid the "stunning" phenomenon, and that it involves low radiation exposure for patients and medical staff.

Seventy-eight of the 420 patients enrolled in the present study had negative results on $99mTcO_4^-$ thyroid static imaging but positive results on $131I$-WBS. These false negative results may be caused by smaller amounts of residual thyroid tissue with a relatively high background of thyroid bed area and surrounding tissue. On the other hand, this study found no false negative cases on $131I$-WBS, thus confirming that $131I$-WBS has a higher sensitivity and can be used as the gold standard for imaging thyroid tissue and metastatic lesions. Seven patients exhibited negative results on both imaging methods, an outcome that may be caused by more thorough thyroidectomy and subsequent lack of thyroid tissue residue. Based on the results of this study, we conclude that positive results on $99mTcO_4^-$ thyroid static imaging can confirm the presence of residual thyroid tissue, whereas negative results cannot conclusively confirm its absence.

Furthermore, $99mTcO_4^-$ thyroid static imaging also revealed some metastatic lesions when used for assessment of the residual thyroid tissue prior to $131I$ therapy in this study. In our patients, SPECT planar imaging had been performed previously; as a result, uptake of the thyroid bed region was found on both imaging studies. If any abnormal uptake was found outside the thyroid, SPECT/CT fusion imaging was subsequently performed to determine the location and nature of the foci. The abnormal uptake of $99mTcO_4^-$ outside the thyroid bed area has been previously reported to be more likely to be caused by lesion metastasis [13], especially in cases of bilateral lung uptake and bone uptake. Herein, the 10 patients with abnormal areas of $99mTcO_4^-$ concentration outside the thyroid bed were confirmed to have lymph node, lung, or bone metastases by $131I$-WBS, SPECT/CT fusion imaging, or ultrasound (Table 2).

Our detailed analysis of the above-mentioned 10 cases further confirmed that some DTC metastases were well-differentiated and showed higher expression of NIS, indicating that they can readily take up and concentrate $99mTcO_4^-$ and $131I$; these characteristics are more common in thyroid follicular carcinoma and thyroid follicular papillary carcinoma. Some studies have shown that the application of $99mTcO_4^-$ WBS combined with SPECT/CT imaging plays a useful role in detecting metastatic lesions of DTC in the neck and chest [13]. Byeong's study revealed that high levels of TSH under stimulation conditions may improve the diagnostic capacity of thyroid static imaging for detecting metastatic lesions of DTC [12].

In this study, thyroid static imaging was performed under stimulation conditions (TSH>30 µIU/ml), demonstrating that it can identify metastatic lesions in certain cases of DTC, potentially associated with high TSH levels. The reason that $99mTcO_4^-$ thyroid static imaging can reveal metastases of DTC may be related to the fact that metastases have higher NIS expression and a higher degree of differentiation, suggesting that they have high $131I$ uptake ability, as well as good susceptibility to $131I$ treatment and thus a better prognosis.

Following observation of the therapeutic effect of $131I$ in clinical work and the identification of metastatic lesions of DTC by $99mTcO_4^-$ thyroid static imaging, the therapeutic effect of $131I$ has been well verified. However, its prognostic ability requires long-term follow-up for verification. Further, the results of our analysis still require confirmation through pathological analysis of the metastatic lesions.

The use of $99mTcO_4^-$ thyroid static imaging can help initially determine the differentiation status of metastatic lesions and identify some metastatic lesions, thus providing better guidance for the selection of therapeutic doses. As $131I$ treatment protocols are established based on the presence of metastases as well as their location, accurately identifying the number, location, and iodine uptake function of the metastatic lesions of thyroid cancer will have great significance in the decision-making regarding the patients’ treatment [21]. Especially, $99mTcO_4^-$ thyroid static imaging is useful for assessing the size, location, and function of residual thyroid tissue before post-DTC $131I$ treatment and for suggesting individualized treatment of DTC patients, as compared to $131I$ imaging. Hence, it should be widely used in the clinical setting. As mentioned above, in the present study, 10 patients with DTC metastases were identified by $99mTcO_4^-$ thyroid static imaging, which provided useful information for the treatment of these patients. Moreover, in some cases, the results were used to adjust the patients’ clinical stages and treatment plans and to predict the efficacy and prognosis of $131I$ treatment;
thus, the procedure has some utility in guiding individualized DTC treatment.

There are some limitations in this study. Although $^{99m}$TcO$_4^-$ thyroid static imaging may be used to suggest the subsequent treatment of DTC patients, pathological examination of the expression of NIS in metastatic lesions and analysis of long-term follow-up data were not conducted; these data will be collected and reported in the future. Further, owing to limitations in the sample size and follow-up time, only partial conclusions can be drawn, and some conclusions are only speculations. The outcomes of the study patients need to be further followed-up for a long time.

In conclusion, $^{99m}$TcO$_4^-$ thyroid static imaging can identify metastatic lesions of DTC, and we speculate that the uptake principle is related to the high expression of NIS and the higher degree of differentiation of these lesions. However, this hypothesis requires further confirmation by pathological examination of the metastatic lesions.

**Conflicts of Interest**

The authors declare no conflict of interest.

**References**


Utility of 99mTcO4- static imaging for detecting metastatic lesions in differentiated thyroid cancer

*Correspondence to*
Xiaoyong Zhang
Department of Radionuclide Treatment Center
Beijing 401 Hospital of Chinese Nuclear Industry
PR China